Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 3, 2008, Pages 97-101

  Rivers, Jason K ^a,b,c,d   Rosoph, Les ^a,b,c,d   Provost, Nathalie ^a,b,c,d   Bissonnette, Robert ^a,b,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Pacific Dermaesthetics   (Canada)

^c North Bay Dermatology Centre   (Canada)

^d INNOVADERM RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; APPLICATION SITE DRYNESS; APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE ULCER; APPLICATION SITE VESICLE; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BLADDER CARCINOMA; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREAM; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HERPES SIMPLEX; HUMAN; LOCAL SKIN REACTION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; OPEN STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; PRURITUS; SKIN EXFOLIATION; SKIN TINGLING; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD; HUMANS; KERATOSIS; MALE; OINTMENTS; TREATMENT OUTCOME;

EID: 63049138720     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.07045     Document Type: Article

References (20)

1. Yantsos VA, Conrad N, Zabawski E, et al. Incipient intraepidermal cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg 1999; 18:3-14.
2. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42:11-7.
3. Frost CA, Green AC. Epidemiology of solar keratoses. Br J Dermatol 1994;131:455-64.
4. Lebwohl M. Actinic keratosis: epidemiology and progression to squamous cell carcinoma. Br J Dermatol 2003;149 Suppl 66:31-3.
5. Black HS, Herd JA, Goldberg LH, et al. Effect of a low-fat diet on the incidence of actinic keratosis. N Engl J Med 1994;330:1272-5.
6. De Hertog SA, Wensveen CA, Bastiaens MT, et al. Relation between smoking and skin cancer. J Clin Oncol 2001;19:231-8.
7. Gupta AK, Cherman AM, Tyring SK. Viral and nonviral uses of imiquimod: a review. J Cutan Med Surg 2004;8:338-52.
8. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002;27: 571-7.
9. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol 2000;43 (Suppl):S6-11.
10. Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J 2004;10:4.
11. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21.
12. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467-73.
13. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55.
14. Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg 2005;31:659-64.
15. Perras C. Imiquimod 5% cream for actinic keratosis. Issues Emerg Health Technol 2004;Sep:1-4.
16. Harrison LI, Skinner SL, Marbury TC, et al. Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms. Arch Dermatol Res 2004;296: 6-11.
17. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47:571-7.
18. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiquimod 5% cream. Br J Dermatol 2003;149 Suppl 66:37-9.
19. Lang PG Jr. Management of actinic keratoses. Compr Ther 2003; 29:108-14.
20. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:23-4.